A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed Neuroblastoma.
Phase of Trial: Phase I/II
Latest Information Update: 04 Nov 2016
At a glance
- Drugs TPI 287 (Primary) ; Irinotecan; Temozolomide
- Indications Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- 19 Jan 2016 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 17 Nov 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 16 Apr 2012 Planned end date changed from 1 Dec 2014 to 1 Dec 2018 as reported by ClinicalTrials.gov.